Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration

Samsung Biologics, a contract development and manufacturing organization (CDMO) and TG Therapeutics, are expanding a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab, an investigational anti-CD20 monoclonal antibody.

TG Therapeutics has completed a rolling submission of a Biologics License Application (BLA) to the U.S. FDA requesting approval of ublituximab, in combination with UKONIQ (umbralisib), TG Therapeutics’ oral once-daily inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with CLL, based primarily on the positive results from the UNITY-CLL Phase 3 trial. Ublituximab was also the subject of two successful Phase 3 trials in patients with relapsing forms of multiple sclerosis (RMS) and a BLA is currently being prepared for this indication.

“We are very glad to be able to flexibly accommodate our client’s expanded needs through our facilities,” John Rim, CEO, Samsung Biologics, commented. “By supporting TG Therapeutics in this partnership, we are contributing to bringing needed treatments to patients around the world, and getting a step closer to our vision of bringing about a better life for humanity.”

Michael S. Weiss, executive chairman and CEO, TG Therapeutics, said, “Samsung is the global leader in biologics manufacturing and we are happy to have them as our partner as we look forward to the potential commercialization of ublituximab across both oncology and autoimmune indications. With the recent positive ULTIMATE I and II MS Phase 3 studies, we re-evaluated our supply needs and were very pleased we were able to secure the long-term capacity we believe we will need to meet the potential global demand for ublituximab. This is an important next step in our [long-standing] relationship with Samsung.”

In order to support all its current and potential clients around the world, Samsung Biologics is currently building its fourth and largest biomanufacturing facility in Incheon, Korea. Upon completion of the said plant in 2023, Samsung Biologics will hold 620,000 liters of biomanufacturing capacity, or approximately a quarter of the entire bio-CMO capacity globally. The company provides contract manufacturing, contract development, and testing services all from a single location, offering end-to-end services for its clients.